MENU
Alnylam

2014 Summer RNAi Roundtable Series

We hosted a series of online “RNAi Roundtables” during July and August, at which Alnylam scientists and key clinical collaborators reviewed recent progress from several “Alnylam 5×15” programs and discussed the related disease areas.


Patisiran and ALN-TTRsc for the treatment of Transthyretin-Mediated Amyloidosis (ATTR)
Tuesday, July 15: 12:30 – 2:00 p.m. ET

  • Jared Gollob, M.D., Vice President, Clinical Research
  • Moderator: John Maraganore, Ph.D., Chief Executive Officer
  • Guest Speaker: Philip N. Hawkins, M.B., B.S., Ph.D., FRCP, Professor of Medicine, National Amyloidosis Centre, University College London Medical School

Advances in Delivery of RNAi Therapeutics with Enhanced Stabilization Chemistry (ESC)-GalNAc-siRNA Conjugates
Tuesday, July 22: 11:00 a.m. – 12:00 p.m. ET

  • Rachel Meyers, Ph.D., Vice President, Research and RNAi Lead Development
  • Moderator: Laurence Reid, Ph.D., Senior Vice President and Chief Business Officer

ALN-HBV for the treatment of Hepatitis B Virus (HBV) Infection
Tuesday, July 29: 9:30 – 10:30 a.m. ET

  • Laura Sepp-Lorenzino, Ph.D., Vice President, Entrepreneur-in-Residence
  • Moderator: Laurence Reid, Ph.D., Senior Vice President and Chief Business Officer
  • Guest Speaker: Graham Foster, Ph.D., FRCP, Professor of Hepatology at Queen Mary University of London

ALN-AT3 for the treatment of Hemophilia and Rare Bleeding Disorders
Thursday, August 7: 9:30 – 10:30 a.m. ET

  • Akin Akinc, Ph.D., Director, Research
  • Moderator: John Maraganore, Ph.D., Chief Executive Officer
  • Guest Speaker: David Lillicrap, M.D., FRCPC, Professor, Department of Pathology and Molecular Medicine at Queen’s University, and Canada Research Chair in Molecular Hemostasis

ALN-CC5 for the treatment of Complement-Mediated Diseases
Wednesday, August 13: 9:30 – 10:30 a.m. ET

  • Benny Sorensen, M.D., Ph.D., Medical Director, Clinical Development
  • Moderator: Barry Greene, President and Chief Operating Officer
  • Guest Speaker: Anita Hill, MBChB (Hons), MRCP, FRCPath, Ph.D., Consultant Haematologist for Leeds Teaching Hospitals NHS Trust, UK, and Honorary Senior Lecturer at the University of Leeds

ALN-PCSsc for the treatment of Hypercholesterolemia
Thursday, August 14: 4:00 – 5:00 p.m. ET

  • Kevin Fitzgerald, Ph.D., Senior Director, Research
  • David Kallend, MBBS, Vice President and Global Medical Director, The Medicines Company
  • Moderator: Akshay Vaishnaw, M.D., Ph.D., Executive Vice President and Chief Medical Officer
  • Guest Speaker: Christie Ballantyne, M.D., Professor of Medicine, Physiology, and Molecular and Human Genetics, and Chief, Department of Medicine, Sections of Cardiology and Cardiovascular Research at Baylor College of Medicine

ALN-AAT for the treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
Wednesday, August 20: 12:30 – 1:30 p.m. ET

  • Rachel Meyers, Ph.D., Vice President, Research and RNAi Lead Development
  • Moderator: Akshay Vaishnaw, M.D., Ph.D., Executive Vice President and Chief Medical Officer
  • Guest Speaker: David Brenner, M.D., Vice Chancellor for Health Sciences and Dean of the School of Medicine at the University of California, San Diego

ALN-AS1 for the treatment of Hepatic Porphyrias
Thursday, August 21: 4:00 – 5:00 p.m. ET

  • Rachel Meyers, Ph.D., Vice President, Research and RNAi Lead Development
  • Moderator: Barry Greene, President and Chief Operating Officer
  • Guest Speaker: Karl Anderson, M.D., FACP, Professor, Departments of Preventive Medicine and Community Health (Division of Human Nutrition) and Internal Medicine (Division of Gastroenterology), and Director, Porphyria Laboratory & Center at the University of Texas Medical Branch